Gaucher Disease Type I Global Clinical Trials Review, H2, 2017

2017-08-30
Price :
Published : Aug-2017
No. of Pages : 56
order by fax Inquire before Buying request discount
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Gaucher Disease Type I to Genetic Disorders Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Gaucher Disease Type I to Genetic Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Gaucher Disease Type I Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profile Snapshots 32
Appendix 54
Abbreviations 54
Definitions 54
Research Methodology 55
Secondary Research 55
About GlobalData 56
Contact Us 56
Source 56

List of Tables
Gaucher Disease Type I Therapeutics, Global, Clinical Trials by Region, 2017* 7
Gaucher Disease Type I Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Gaucher Disease Type I Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Gaucher Disease Type I Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Gaucher Disease Type I Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Gaucher Disease Type I Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Gaucher Disease Type I Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
Gaucher Disease Type I Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
Proportion of Gaucher Disease Type I to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 16
Gaucher Disease Type I Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Gaucher Disease Type I Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Gaucher Disease Type I to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 19
Gaucher Disease Type I Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Gaucher Disease Type I Therapeutics, Global, Clinical Trials by Phase, 2017* 21
Gaucher Disease Type I Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
Gaucher Disease Type I Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Gaucher Disease Type I Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Gaucher Disease Type I Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Gaucher Disease Type I Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
Gaucher Disease Type I Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Gaucher Disease Type I Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Gaucher Disease Type I Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31

List of Figures
Gaucher Disease Type I Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Gaucher Disease Type I Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Gaucher Disease Type I Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Gaucher Disease Type I Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Gaucher Disease Type I Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Gaucher Disease Type I Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Gaucher Disease Type I Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
Gaucher Disease Type I Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15
Proportion of Gaucher Disease Type I to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 16
Gaucher Disease Type I Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Gaucher Disease Type I Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Gaucher Disease Type I to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 19
Gaucher Disease Type I Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Gaucher Disease Type I Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
Gaucher Disease Type I Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
Gaucher Disease Type I Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Gaucher Disease Type I Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Gaucher Disease Type I Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Gaucher Disease Type I Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
Gaucher Disease Type I Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Gaucher Disease Type I Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Gaucher Disease Type I Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31
GlobalData Methodology 55
Filed in: Pharmaceutical
Publisher : GlobalData